CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash flows from operating activities:
Net loss	$ (19,845,620)	$ (8,845,351)
Adjustments to reconcile net loss to net cash used by operating activities:
Non-cash restricted stock unit compensation	(226,014)	1,515,804
Depreciation and amortization	446,334	280,073
Amortization of right of use asset	129,045	0
Impairment of patents	431,426	0
Bad debt expense (recovery)	24,354	22,689
Stock-based compensation	1,548,689	2,225,613
Foreign currency transaction loss	3,736,296	1,071,376
Changes in operating assets and liabilities:
Grants and accounts receivable	(943,398)	(726,560)
Inventories	(589,483)	(1,102,610)
Prepaid expenses and other current assets	1,360,675	1,155,180
Other assets	54,658	(83,761)
Accounts payable and accrued expenses	(2,286,125)	107,065
Net cash used in operating activities	(16,159,163)	(4,380,482)
Cash flows from investing activities:
Purchases of property and equipment	(5,234,163)	(1,217,254)
Payments for patent costs	(298,800)	(373,764)
Net cash used in investing activities	(5,532,963)	(1,591,018)
Cash flows from financing activities:
Equity contributions - net of fees incurred	(40,359)	0
Proceeds from exercise of stock options	0	206,405
Net cash provided by (used in) financing activities	(40,359)	206,405
Effect of exchange rates on cash	(241,167)	(47,428)
Net change in cash, cash equivalents and restricted cash	(21,973,652)	(5,812,523)
Cash, cash equivalents and restricted cash - beginning of period	53,825,166	71,421,601
Cash, cash equivalents and restricted cash - end of period	31,851,514	65,609,078
Supplemental disclosure of cash flow information:
Cash paid during the period for interest	0	0
Supplemental disclosure of non-cash financing activities:
Issuance of common stock to vendor in lieu of cash payment	42,499	0
Capital expenditures included in accounts payable	229,824	0
Settlement of accrued bonuses with restricted stock units	$ 260,235	$ 692,311